![ASHP](/-/media/assets/home-page/logo.png)
Mpox Outbreak
Cases of mpox have continued to rise since May 2022 when the virus was reported in areas throughout the United States and globally. Mpox is a viral disease spread through close and intimate contact. On August 14, 2024 the World Health Organization (WHO) declared that the most recent upsurge in a new strain of mpox cases had reached the level of a public health emergency of international concern (PHEIC). This resource center provides access to countermeasures and patient care considerations for the ongoing mpox outbreak.
In response to advocacy from ASHP and other pharmacy organizations, HHS has authorized pharmacists, pharmacy interns, and pharmacy technicians supervised by a pharmacist, to prescribe, dispense, or administer vaccines and therapeutics for smallpox (variola virus), mpox virus, or other orthopoxviruses. The authorization extends to pharmacists and technicians whose licensure has lapsed or expired in the past five years. HHS used its authority under the Public Readiness and Emergency Preparedness (PREP) Act in order to improve access to vaccines and treatments necessary to address the mpox outbreak.
Vaccination may be recommended for individuals who may have close personal contact with someone infected with mpox based on risk factors (Pre-Exposure Prophylaxis – PrEP) or who may have been exposed to the virus (Post-Exposure Prophylaxis – PEP). Individuals who have recovered from mpox are not recommended to receive vaccination and boosters are not currently recommended. For more information, visit CDC Considerations for Mpox Vaccination.
Updated on August 29, 2024
![General Facts](/-/media/assets/pharmacy-practice/resource-centers/monkeypox/images/general-facts-400.png?h=400&w=400&la=en&hash=C507088E237DB6EA8DBC52804EC35368)
General
- CDC Outbreak 2022: Situation Summary
- CDC Disease State Overview
- FDA Mpox Response
- World Health Organization Mpox Outbreak Resources
- Infectious Diseases Society of America Mpox: What You Need to Know
- [SafeMedication.com] Should I be Concerned about a Mpox Outbreak? (Patient Information)
- [SafeMedication.com] How do I Get Mpox? (Patient Information)
![Prevention](/-/media/assets/pharmacy-practice/resource-centers/monkeypox/images/prevention-new-400.png?h=400&w=400&la=en&hash=0AF54AF2BC4EB05FCB45A42637891EC4)
Prevention
- FDA Product Information – Jynneos vaccine
- CDC Jynneos Interim-Considerations
- CDC Clinical Outreach and Communication Activity (COCA) – Mpox Update: Clinical Management and Outbreaks
- AHFS Jynneos Monograph pdf
- CDC ACAM2000 Vaccine Interim Considerations
- CDC Mpox Prevention Steps
- Tips Regarding Exposure – Safer Sex & Social Gatherings
- AHFS ACAM2000 Smallpox Vaccine Monograph pdf
- [SafeMedication.com] How do I Keep from Getting Mpox? (Patient Information)
![Treatment](/-/media/assets/pharmacy-practice/resource-centers/monkeypox/images/treatment-400.png?h=400&w=400&la=en&hash=7D5E2CA6B6296F8B4213488A5278E9C8)
Treatment
- CDC Clinical Guidance for the Treatment of Mpox
- CDC Updates about Clinical Diagnosis and Treatment Summary (WARNING: Graphic Images)
- [AJHP] The 2022 Human Monkeypox Outbreak: Clinical Review and Management Guidance
- AHFS Tecovirimat Monograph pdf
- Information for Healthcare Providers: Tecovirimat (TPOXX) for Treatment of Mpox
- CDC Patient’s Guide to Treatment with TPOXX
- AHFS Cidofovir Monograph pdf
- Vaccine Immune Globulin Intravenous (VIGIV)
- [SafeMedication.com] I Have Mpox: What should I do? (Patient Information)